The crucial roles of long noncoding RNA SNHGs in lung cancer

被引:0
作者
Feng Chen
Fa Zhang
Yu-fang Leng
Ya-jing Shi
Jian-ming Zhang
Yong-qiang Liu
机构
[1] First Hospital of Lanzhou University,Department of Anesthesiology
[2] The First Clinical Medical College of Lanzhou University,Department of Urology
[3] Gansu Provincial Hospital,undefined
来源
Clinical and Translational Oncology | 2022年 / 24卷
关键词
lncRNA; Small nucleolar RNA host genes; Lung cancer; Biological characteristics; Therapeutic target;
D O I
暂无
中图分类号
学科分类号
摘要
Lung cancer is one of the most common malignant tumors with growing morbidity and mortality worldwide. Several treatments are used to manage lung cancer, including surgery, radiotherapy and chemotherapy, as well as molecular-targeted therapy. However, the current measures are still far from satisfactory. Therefore, the current research should focus on exploring the molecular mechanism and then finding an effective treatment. Interestingly, we and others have embarked on a line of investigations focused on the mechanism of lung cancer. Specifically, lncRNA small nucleolar RNA host gene has been shown to be associated with biological characteristics and therapeutic resistance of lung cancer. In addition, small nucleolar RNA host genes may be used as diagnostic biomarker in the future. Herein, we will provide a brief review demonstrating the importance of small nucleolar RNA host genes in lung cancer, especially non-small cell lung cancer. Although lncRNA has shown a crucial role in tumor-related research, a large number of studies are needed to validate its clinical application in the future.
引用
收藏
页码:2272 / 2284
页数:12
相关论文
共 467 条
[1]  
Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 E359-E386
[2]  
Soerjomataram I(2016)ALK inhibitors in non-small cell lung cancer: the latest evidence and developments Ther Adv Med Oncol 8 32-47
[3]  
Dikshit R(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[4]  
Eser S(2021)Cancer statistics, 2021 CA Cancer J Clin 71 7-33
[5]  
Mathers C(2008)Lung cancer N Engl J Med 359 1367-1380
[6]  
Rebelo M(2002)Pathology of lung cancer Clin Chest Med 23 65-81
[7]  
Parkin DM(2018)Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors Drug Discov Today 23 745-753
[8]  
Forman D(2022)Long non-coding MELTF Antisense RNA 1 promotes and prognosis the progression of non-small cell lung cancer by targeting miR-1299 Bioengineered 13 10594-10604
[9]  
Bray F(2022)Poor prognosis of intra-tumoural TRBV6-6 variants in EGFR-mutant NSCLC: results from the ADJUVANT-CTONG1104 trial Clin Transl Med 12 237-108
[10]  
Sullivan I(2016)Implications of microRNAs in the treatment of gefitinib-resistant non-small cell lung cancer Int J Mol Sci 17 101-46